|
Products |
| Products |
|
Diseases |  |
News |  |
| «12...277278279280281282283284285286287...49464947» |
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Real-World Evaluation of Trastuzumab Deruxtecan Administration, Compliance, and Dose Utilization in Chinese Patients With HER2-Positive Advanced Breast Cancer () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2266;
However, the administered dose (4-5 mg/kg) was lower than recommended, and treatment intervals were longer than the recommended 21 days. A small percentage of patients received standard treatment.
- Bavencio (avelumab) / EMD Serono, Blincyto (blinatumomab) / Astellas, Amgen, Alecensa (alectinib) / Roche
Synthetic Control Arms Data Driven by Artificial Intelligence: A Viable Alternative to Placebo Cohorts in Comparative Clinical Studies? () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2217;
P=N/A
They could also address ethical and recruitment challenges in placebo-controlled trials by enabling robust sample sizes in rare and severe disease studies. However, digital twins are in validation stages with preliminary results, and the use of RWE and historical data for SCAs has been accepted as supplementary evidence alongside placebo RCTs.
- Rinvoq (upadacitinib) / AbbVie
Using Chat-GPT for Completing Quality Assessment Questionnaires in Systematic Literature Reviews () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2210;
Custom Chat-GPT applications have the potential to save significant time, effort, and monetary resources. However, outputs from these AI tools need to be corrected and/or validated by experienced HEOR experts.
- Pemazyre (pemigatinib) / Incyte
Cost-Effectiveness of Pemigatinib for Patients With Advanced Intrahepatic Cholangiocarcinoma and FGFR2 Fusions/Rearrangements: 2024 FIGHT-202 Trial Final Results () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2181;
However, outputs from these AI tools need to be corrected and/or validated by experienced HEOR experts. Based on the latest efficacy data, pemigatinib shows cost-effectiveness over mFOLFOX and 5-FU/LV for Taiwanese patients with advanced ICC and FGFR2 fusions/rearrangements under Taiwan NHI
- Landscape of Intrahepatic Cholangiocarcinoma (IHC) in Brazilian Public Healthcare System and Monitoring of the Technological Horizon () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2177;
A progressive increase in diagnoses, number and cost of hospitalization and deaths was observed. According to the data, the availability of new therapies could change the journey of advanced IHC patients in Brazil who, until recently, were solely treated with traditional chemotherapies.
- Improving Access to Innovative Therapies for Rare Bleeding Disorders: Evidence From High Income Countries () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2176;
High costs often pose barriers, but PASs and cost-minimization measures can positively influence decisions. Continued HTA methods advancements, like CDA-AMC's "Time-Limited Reimbursement Recommendations", could enhance accessibility and affordability of these therapies, ensuring timely and effective treatment for patients with RBDs.
- Vabysmo (faricimab-svoa) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Efficacy and Safety of Angiogenesis Inhibitors for Diabetic Macular Edema Therapy: Systematic Review and Network Meta-Analysis () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2169;
Systematic review (SR) of randomized clinical trials (RCTs) published before December 2022 was carried out via PRISMA guideline to evaluate the comparative efficacy and safety of faricimab 6 mg vs aflibercept 2 mg, ranibizumab 0.3/0.5 mg. 1-year efficacy and safety of faricimab in patients with DME are comparable to other angiogenesis inhibitors.
- Tepmetko (tepotinib) / EMD Serono
Comparing Treatment Strategies Accounting for Subsequent Treatments: Combining Propensity Scores With Inverse Probability of Censoring Weights to Estimate Comparative Effectiveness in Met Exon 14 (METex14) Skipping NSCLC () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2163;
Adjustment for subsequent treatment is known to be important in health technology assessment but is challenging with external control studies, requiring adjustments for patient characteristics at baseline, and for treatment switches over time. Our study demonstrates how IPCW can be combined with PS to adjust for treatment switches in this context.
- Venclexta (venetoclax) / Roche, AbbVie, Rydapt (midostaurin) / Novartis
Real-World Treatment of Newly Diagnosed Patients With Acute Myeloid Leukemia and Aged Between 60 and 75 Years: Analysis of Key Drivers for Chemotherapy Selection in France and Germany () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2162;
Favorable and intermediate ELN risk molecular markers (including NPM1 mutations) are considered for borderline fit patients. We observed higher non-testing rates in France among fit patients and in Germany among unfit patients.
- Qarziba (dinutuximab beta) / Jazz
Chemoimmunotherapy With Dinutuximab Beta Compared to Chemotherapy Regimens in Patients With Relapsed/Refractory Neuroblastoma: Systematic Literature Review and Indirect Treatment Comparison () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2154;
Our results demonstrate improved objective response and progression free survival outcomes with dinutuximab beta chemoimmunotherapy in relapsed/refractory neuroblastoma and support recommendations for its use in this setting. Analysis with individual patient data adjusted for predictors of outcomes would allow for a more precise estimate of treatment effect.
- Orserdu (elacestrant) / Menarini
Elacestrant vs Everolimus + Exemestane in Patients With ER+/HER2- ESR1-Mutated Advanced/Metastatic Breast Cancer (mBC) With Prior Endocrine Therapy + CDK4/6 Inhibitor ?12 Months: Combining Real-World and Clinical Trial Data () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2138;
Analysis with individual patient data adjusted for predictors of outcomes would allow for a more precise estimate of treatment effect. Our findings indicate that in patients with ER+/HER2- ESR1 -mutated mBC who received prior ET+CDK4/6i ?12 months, treatment with elacestrant is associated with a significant 41% reduction in the risk of progression or death compared to everolimus + exemestane.
- Trodelvy (sacituzumab govitecan-hziy) / Gilead, Talzenna (talazoparib) / Pfizer, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Comparative Analysis of HTA Decisions for Metastatic Breast Cancer Treatments in Nordic Countries () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2129;
Our findings indicate that in patients with ER+/HER2- ESR1 -mutated mBC who received prior ET+CDK4/6i ?12 months, treatment with elacestrant is associated with a significant 41% reduction in the risk of progression or death compared to everolimus + exemestane. Denmark exhibited more restrictive recommendations, with certain treatments like Trodelvy
- Rozlytrek (entrectinib) / Roche
Quantifying Bias in Matching Adjusted Indirect Comparisons (MAIC): A Case Study With Entrectinib in Metastatic ROS-1 Positive Non-Small Cell Lung Cancer (NSCLC) () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2095;
This study presents the first comprehensive applications of quantitative bias analysis to MAICs. It demonstrates the usefulness of these approaches in supporting the robustness of the efficacy results of MAICs to residual bias and missingness assumptions, even in the presence of a limited sample size.
- Inlyta (axitinib) / Pfizer
Budget Impact Analysis of Axitinib (Caxetib () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2087;
It demonstrates the usefulness of these approaches in supporting the robustness of the efficacy results of MAICs to residual bias and missingness assumptions, even in the presence of a limited sample size. A 5-year Budget Impact Analysis (BIA) model was developed to estimate the incremental BI for 171 patients in treatment for 2 nd line mRCC at the IMSS with the adoption of new Axitinib (Caxetib
- Impact of Pharmacological Interventions on Clinical and Humanistic Outcomes in Idiopathic Pulmonary Fibrosis (IPF): A Systematic Literature Review (SLR) () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2020;
A 5-year Budget Impact Analysis (BIA) model was developed to estimate the incremental BI for 171 patients in treatment for 2 nd line mRCC at the IMSS with the adoption of new Axitinib (Caxetib Mean CFB in absolute FVC was less with nintedanib+pirfenidone (
- Insights From Randomized Controlled Trials on the Efficacy and Safety of Pharmacological Therapies for Differentiated Thyroid Cancer: A Systematic Review () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2014;
Despite modest progress in the general DTC population, lenvatinib has revolutionized RAIR-DTC treatment by delivering a higher response rate and extended survival, although with a higher adverse event risk. Therefore, further DTC research needs to be conducted both in the broader population and in the RAIR-DTC population.
- Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
A Budget Impact Analysis of Introducing Filgotinib as a First-Line Treatment for Moderate to Severe Ulcerative Colitis in Greece () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1973;
Filgotinib's favorable economic impact, alongside its clinical efficacy, supports its potential as a valuable addition to current treatment options for moderate to severe ulcerative colitis, promising both healthcare cost efficiencies and improved patient outcomes in the Greek healthcare setting. This study provides compelling evidence for policymakers and healthcare providers considering the economic impact of filgotinib's inclusion in UC management protocols.
- Awiqli (insulin icodec) / Novo Nordisk
A Systematic Literature Review and Network Meta Analysis of Insulin Icodec With Other Basal Insulins in Patients With Type 2 Diabetes Switching From Basal Insulin Regimens () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1927;
A SLR was conducted in October 2023 to identify relevant randomised controlled trials (RCTs) examining treatments of interest (insulin icodec, insulin glargine [IGlar U100, IGlar U300], insulin detemir, and insulin degludec [U100 and U200]) in this population. For patients with T2D switching from basal insulin, insulin icodec resulted in greater HbA 1c reductions at 26
- Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Tresiba (insulin degludec) / Novo Nordisk
Budget Impact Model for Insulin Glargine-300U/mL (Gla-300) vs Insulin Degludec 100 U/mL in the Treatment of Type 1 Diabetes Mellitus Based on the Inrange Study () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1920;
the proportion of eligible patients had considerable influence on the net financial impact. The use of Glargine-300U/mL and the overall of its clinical and economic benefit is the most rational strategy to reduce diabetes burden and its additional costs, Further studies are suggested to confirm this analysis.
- Alecensa (alectinib) / Roche
Cost-Effectiveness Analysis of Adjuvant Alectinib Compared to Platinum-Based Adjuvant Chemotherapy in Patients With Resectable ALK-Positive NSCLC in Italy () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1894;
[1] Araghi M, Mannani R, Heidarnejad Maleki A, Hamidi A, Rostami S, Safa SH, Faramarzi F, Khorasani S, Alimohammadi M, Tahmasebi S, Akhavan-Sigari R. Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell Int.
- Actemra IV (tocilizumab) / Roche, JW Pharma, Tyenne (tocilizumab-aazg) / Fresenius Kabi, Rituxan (rituximab) / Roche
Rheumatoid Arthritis, Cost-Effectiveness Analysis of Biosimilar Tocilizumab in Spain () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1865;
The model included abatacept, biosimilar adalimumab, baricitinib, certolizumab, etanercept, filgotinib, golimumab, infliximab, rituximab, sarilumab, reference and biosimilar tocilizumab, tofacitinib, and upadacitinib... Biosimilar tocilizumab has proven to be a cost-effective alternative for the treatment of rheumatoid arthritis patients, even against the least expensive available biological or targeted synthetic DMARD comparator in Spain in a lifetime-horizon perspective.
- Brukinsa (zanubrutinib) / BeiGene, Calquence (acalabrutinib) / AstraZeneca, Imbruvica (ibrutinib) / AbbVie, J&J
The Importance of Assessment Design When Capturing Reasons for Therapeutic Change in Cancer Care () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1850;
Adverse events were more commonly cited by physicians at treatment discontinuation, while progression was the predominant reason at new treatment initiation. The results provide insight into cancer care clinical decision-making and highlight the value of chart review design for assessing reasons for therapeutic change.
- Characteristics of High-Cost Medicines in the Context of Health Judicialization in Brazil: A Scoping Review () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1846;
The results provide insight into cancer care clinical decision-making and highlight the value of chart review design for assessing reasons for therapeutic change. The heterogeneity in how judicialized medicines were brought into the studies and the conceptual imprecision identified make it challenging to get a clearer view of the importance of HCM in the scenario of health lititigation in Brazil.
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Assessing Trends in European Union () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1835;
The heterogeneity in how judicialized medicines were brought into the studies and the conceptual imprecision identified make it challenging to get a clearer view of the importance of HCM in the scenario of health lititigation in Brazil. In Germany, ADC submissions are increasingly being rated as having
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Budget Impact and Cost-Utility Analysis of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Renal Cell Cancer (aRCC) in Costa Rica () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1768;
Immunotherapy (IO) has significantly improved survival rates and quality of life versus sunitinib for the treatment of aRCC. Nivolumab plus ipilimumab represents a cost-saving option for 1L aRCC treatment and a cost-effective regimen for patients with intermediate and poor-risk aRCC in Costa Rica.
- Vabysmo (faricimab-svoa) / Roche
Comparative Efficacy and Safety of Faricimab for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion (RVO): A Systematic Literature Review and Network Meta-Analysis () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1765;
The results indicate that faricimab is associated with non-inferior vision changes and comparable or numerically greater retinal drying vs. anti-VEGF treatments. The results also suggest that the safety profile for faricimab is comparable to other anti-VEGFs, which have well-established safety profiles.
- Evaluating the Optimal TKI for Patients With ALK Positive Advanced Non-Small-Cell Lung Cancer (aNSCLC) in the First Line (1L) Setting: An Updated Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1757;
With the unprecedented CROWN 5Y data (Solomon et al., JCO 2024), the relative effect of 1L lorlatinib is significantly improved vs. other TKIs. Totality of evidence across available NMAs consistently support lorlatinib as preferred 1L treatment of choice for ALK+ aNSCLC patients.
- Brukinsa (zanubrutinib) / BeiGene
Cost-Effectiveness of Zanubrutinib + Obinutuzumab for Treatment of Relapsed or Refractory Follicular Lymphoma in the United States () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1750;
P2
This study evaluates the cost-effectiveness of Z+O compared with mosunetuzumab (mosun) from the United States (US) payer perspective over a 40-year (lifetime) horizon. This model-based study suggests that Z+O is a cost-effective treatment option compared to mosun for 3L+ R/R FL in the US.
- Nerlynx (neratinib) / Puma
A Visual Representation of the Observational Study of Extended Adjuvant Neratinib in HER2+ Early Breast Cancer (EBC) in the Context of the European Early Access Program (EAP): Near Study Final Results () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1735;
Results of this study were consistent with previous data. Advanced visualizations methods support the communication of results.
- Perjeta (pertuzumab) / Roche
Cost-Effectiveness Analysis (CEA) of Pertuzumab and Trastuzumab (PH) + Chemotherapy (CT) Versus H + CT in HER2-Positive Early Breast Cancer (EBC): Updated Model Using Data From the 8.4-Year Follow-up of APHINITY () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1724;
P3
Adding more efficacious, but more costly, MBC treatments into the model reduced the ICER considerably in the three countries explored, highlighting the importance of optimal treatment in the early, curative setting to avoid metastasis and more costly treatments. These findings are likely to be applicable to other early oncology settings/models.
- Evaluating the Cost Benefit of Fixed-Duration Targeted Therapy in First Line (1ST L) in Chronic Lymphocytic Leukemia (CLL ): A Real-World Analysis Using Hungarian Claims Data () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1722;
These findings are likely to be applicable to other early oncology settings/models. OBJECTIVES: In CLL fixed-duration treatment are available with reimbursement from 2020 (mono, venetoclax-rituximab 2 nd L) and from 2022 (venetoclax- obinutuzumab
- Alecensa (alectinib) / Roche
Cost of Implementing Alectinib as an Adjuvant Treatment for ALK+ Non-Small Cell Lung Cancer in Denmark (C-ALINA) () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1711;
OBJECTIVES: In CLL fixed-duration treatment are available with reimbursement from 2020 (mono, venetoclax-rituximab 2 nd L) and from 2022 (venetoclax- obinutuzumab Alectinib is highly cost-effective with a limited budget impact as an adjuvant treatment for ALK + NSCLC patients, as the cost of alectinib is almost completely offset by reducing the cost of treating patients in the metastatic setting.
- Vabysmo (faricimab-svoa) / Roche
Budget Impact of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (nAMD) in Ireland () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1679;
By allowing safe extension of treatment intervals without compromising efficacy, faricimab reduces the treatment burden on patients and caregivers whilst also optimising healthcare resource utilisation, leading to long-term cost savings. It is noted that our analysis does not account for additional indirect savings, such as improved patient quality of life and productivity gains.
- A Systematic Literature Review (SLR) of the Clinical Efficacy and Safety Evidence Associated With Treatments for Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Progressed on Prior Therapies () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1645;
Discontinuations due to adverse events (AEs; n=14) ranged from 0% (atezolizumab) to 40% of patients (nintedanib+docetaxel)... Outcomes with current treatments after progression on platinum-based chemotherapy and anti-PD-1/PD-L1 inhibitors remain poor, highlighting an unmet medical need in the metastatic NSCLC 1L+ population.
- Alecensa (alectinib) / Roche
The Impact of Adjuvant Alectinib in Reducing Recurrences and Recurrence-Related Treatment Costs in Resected Early-Stage ALK+ Non-Small Cell Lung Cancer Across Canada () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1603;
P3
Treatment with adjuvant alectinib may result in a considerable population-level reduction of recurrences in resected stage IB-IIIA ALK+ NSCLC patients across Canada. This translates to a substantial decrease in the economic burden of the disease.
- Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
A Budget Impact Analysis of Introducing Filgotinib for the Treatment of Rheumatoid Arthritis in Greece () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1598;
The introduction of filgotinib offers significant potential for cost savings to third-party payers primarily by reducing drug acquisition and administration expenses. This analysis highlights filgotinib's valuable economic benefits, positioning it as an advantageous option for RA management within financially constrained healthcare systems.
- Vanflyta (quizartinib) / Daiichi Sankyo
Population-Average Effect Estimates of Quizartinib and Midostaurin in Newly Diagnosed Patients With FLT3-Internal-Tandem-Duplication-Positive Acute Myeloid Leukaemia, Using Multi-Level Network Meta-Regression () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1541;
P3
ML-NMR offers several advantages over traditional population adjustment methods. However, caution is advised when interpreting results and applying them to economic models as ML-NMR typically targets a population-average conditional treatment effect, which differs from the population-average marginal treatment effect.
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Cost-Utility Analysis of Trastuzumab Deruxtecan Versus Treatment of Physician () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1527;
TPC was either capecitabine plus trastuzumab or capecitabine plus lapatinib. T-DXd appears not cost-effective compared with TPC for HER2-positive mBC patients who were refractory or resistant to trastuzumab emtansine in China.
- Utilizing Generative AI Technology for Comprehensive HTA Report Analysis () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1493;
Primary and secondary endpoints varied: Cabozantinib focused on overall survival (OS) with PFS and ORR as secondary, while Atezolizumab plus Bevacizumab and Regorafenib emphasized OS and PFS with additional endpoints like ORR, TTP, DCR, and quality of life...All Generative-AI responses were validated by human-in-the-loop. CONCLUSIONS : Generative-AI technology can provide valuable insights and comprehensive analysis of HTA reports and makes navigating the complex landscape of global health technology assessments easy.
- erlotinib / Generic mfg.
Can Artificial Intelligence Be Used to Improve the Incremental Cost Effectiveness Ratio (ICER): Modelling Utilities As Functions of Health States in Non Small Cell Lung Cancer by Extrapolating Beyond Trial Follow Up () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1467;
The use of ML through SR was shown in this case to improve model fit and lower the ICER compared to standard OLS methods, while ensuring improved goodness of fit. SR, while apparently improving fit and lowering the ICER, is complex and requires further testing in more datasets.
- Vitrakvi (larotrectinib) / Bayer
Applications of Bayesian Borrowing for Assessing Treatment Effects in Clinical Trials () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1446;
BB has the potential to significantly improve the precision and robustness of treatment effect assessments. This review underscores the necessity for continued research in Bayesian methodologies to address existing limitations and expand their applicability in health research.
- tofacitinib / Generic mfg.
Risk of Cardiovascular Events, Cancer, and All-Cause Mortality in JAK Inhibitors Compared to TNF Inhibitors: Analysis of a Large Real-World Claims Database () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1428;
P3b/4
OBJECTIVES: The ORAL Surveillance randomized safety trial (NCT02092467) showed an association between tofacitinib, a Janus kinase inhibitor (JAKi) and an increased risk of serious cardiovascular events... Based on an analysis of a large secondary claims database, the risk of all-cause and CV mortality, and newly diagnosed cancer, were higher in patients initiating JAKis compared to those treated with TNFis confirming the results coming from the randomized safety trial.
- Anluoqing (envonalkib) / Sino Biopharm, Shouyao Holdings
Economic Evaluation of Envonalkib, Iruplinalkib, and Critizonib in the Treatment of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer in China () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1415;
P3
Based on an analysis of a large secondary claims database, the risk of all-cause and CV mortality, and newly diagnosed cancer, were higher in patients initiating JAKis compared to those treated with TNFis confirming the results coming from the randomized safety trial. Envonalkib is the more economical compared with iruplinalkib and critizonib at the set price(1161.78 dollar), and iruplinalkib are cost-saving and utility-increasing compared to critizonib, which can help healthcare system in making optimal policies and help clinicians in the medication of patients.
- Dupixent (dupilumab) / Sanofi, Regeneron, Rinvoq (upadacitinib) / AbbVie
Cost per Responder in Brazil (EASI-75, EASI90 and ?NRS ?4) of Biologics and JAK Inhibitors Based on a Network-Meta-Analysis of Therapies for Atopic Dermatitis. () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1403;
Despite not being obligatory, JAK inhibitors showcase notable cost-efficacy, providing an alternative to biological treatments. Decision-makers should leverage cost-effectiveness analyses for informed resource management and prioritize treatments that maximize clinical benefits and minimize costs.
- Lorbrena (lorlatinib) / Pfizer
Modeling Challenges for Cancer Drugs With Unprecedented Outcomes: Lorlatinib in the First Line Setting of ALK+ aNSCLS As a Case Study () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1324;
Piecewise models have provided better long-term estimates but uncertainties remain. Flexible methods are expected to be required for OS, and additional methods such as mixture cure should be explored.
- octreotide acetate / Generic mfg.
Long-Acting Somatostatin Analogues Treatment Patterns and Outcomes in Neuroendocrine Tumor Patients: An Italian Propensity Score Matched Cohort Study () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1291;
In subsequent treatments, most patients receive SSA with additional therapies. First-line long-acting octreotide and lanreotide showed comparable PFS and OS.
- A Systematic Review of Pharmacological Interventions for Hidradenitis Suppurativa: A Focus on Clinical Response, Quality of Life, and Safety () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1258;
The results of this review demonstrate the possibility of highly personalized treatment approaches for HS management, including adalimumab and povorcitinib. The optimization of HS care requires further research on long-term outcomes.
- Vabysmo (faricimab-svoa) / Roche
From Clinical Trials to RWE: Defining Faricimab Value Drivers in Neovascular Age Related Macular Degeneration Through a Cost Utility Analysis () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1255;
Faricimab, with CTs-based compliance, is a cost-effective option compared to real-world SoC for Italian nAMD patients, with a deterministic ICUR below the recently proposed thresholds for the health technology assessment. This study will also allow to further investigate real world anti-VEGFs measured appropriateness impact on CUA.
- Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lumiere (bevacizumab biosimilar) / Elea Labs
Budget Impact of Intravitreal Bevacizumab for the Treatment of Age-Related Macular Degeneration in the Argentinian Health System () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1236;
The Argentinian Regulatory Agency (ANMAT) approved an exclusive intraocular Bevacizumab (Lumiere)... Increase of intravitreal Bevacizumab for managing AMD could contribute to costs saving, ranging from US$49,135,031 to US$297,323,282 over a 5-year period time.
- Perjeta (pertuzumab) / Roche
Cost Comparison Between the Use of Pertuzumab-Trastuzumab SC and IV Formulations to Treat HER2+ Breast Cancer Patients in Algeria () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1225;
This research highlights the cost reductions associated with switching to another administration route at different levels. It also underscores the potential enhancement in patient access.